Searched for
RHIZEN PHARMA
Alembic Pharma's revival on the cards: Why it is stock pick of the weekAlembic Pharma is looking forward to high growth with API and RoW businesses reporting decent growth. Besides, new products in pipeline and...- Rhizen's cancer drug Umbralisib gets USFDA nod: Alembic PharmaAlembic Pharma on Tuesday said its associate company Rhizen Pharmaceuticals AG's product Umbralisib, which was licensed to TG Therapeutics,...
- Rhizen receives USFDA orphan drug designation for cancer drugThe US Food and Drug Administration (USFDA) has granted orphan drug designation for Tenalisib (RP6530) for the treatment of patients with p...
- Alembic Pharma arm inks pact with Curon to develop cancer treatment drug in Greater ChinaAs per the agreement, Rhizen will receive an undisclosed upfront cash payment and is eligible to receive additional development and commerc...
- Alembic Pharma raises Rs. 750 crore via QIPThe issue was subscribed at a price of Rs. 932 a share, lower than Thursday’s close at Rs. 1081.55 a share on Bombay Stock Exchange.
- Alembic Pharma arm ties up with Novartis for drug developmentAlembic Pharmaceuticals group firm Rhizen Pharmaceuticals SA has entered into an exclusive worldwide license agreement with Novartis.
Load More